🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are escalating worldwide, with figures suggesting in excess of 82 million instances each year. Especially elevated rates are reported in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the face of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options currently available.”

Public health authorities are deeply concerned about the rise in antibiotic-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This STI can lead to major issues, including infertility. Scientists hope that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in concurrent days. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This milestone represents a significant shift in the therapy of superbug gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Data and Worldwide Availability

As per data released by a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which uses two antibiotics. The study involved nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the authority to register and commercialise the drug in numerous regions with limited resources.

Doctors directly involved have shared optimism. Access to a single-dose, oral treatment of this kind is seen as a "game-changer" for public health efforts. This is deemed vital to reduce the burden of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea globally.